Pretransplant increasing rate of lactate dehydrogenase as a predictor of transplant outcomes for patients with myeloid hematological malignancies
- 8 March 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (7), 1732-1736
- https://doi.org/10.1038/s41409-021-01241-w
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Current Use of and Trends in Hematopoietic Cell Transplantation in the United StatesTransplantation and Cellular Therapy, 2020
- Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysisBone Marrow Transplantation, 2019
- Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysisLeukemia, 2019
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationBone Marrow Transplantation, 2018
- Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CRBone Marrow Transplantation, 2018
- Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantationBlood, 2014
- Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction FailureJournal of Clinical Oncology, 2010
- High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell TransplantationTransplantation and Cellular Therapy, 2006
- Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-upBone Marrow Transplantation, 2005
- Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationTransplantation and Cellular Therapy, 2005